Patents Examined by Hong Liu
-
Patent number: 6825198Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.Type: GrantFiled: May 28, 2002Date of Patent: November 30, 2004Assignee: Pfizer IncInventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr.
-
Patent number: 6825188Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.Type: GrantFiled: October 22, 2003Date of Patent: November 30, 2004Assignee: SmithKline Beecham CorporationInventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
-
Patent number: 6821972Abstract: Compounds of formula (I): and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a PCP-mediated condition or disease using the same.Type: GrantFiled: March 29, 2002Date of Patent: November 23, 2004Assignee: Pfizer Inc.Inventors: Simon Bailey, Paul Vincent Fish, Kim James, Gavin Alistar Whitlock
-
Patent number: 6821976Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.Type: GrantFiled: July 22, 2002Date of Patent: November 23, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
-
Patent number: 6818767Abstract: Quinoline derivatives are useful as neuropeptide Y (NPY) receptor ligands and are particularly effective as neuropeptide Y (NPY) antagonists. These compounds are useful in pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders, or obesity.Type: GrantFiled: May 20, 2002Date of Patent: November 16, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Werner Mueller, Werner Neidhart, Philippe Pflieger, Jean-Marc Plancher
-
Patent number: 6812229Abstract: It is to provide a novel fungicide having high controlling effects on plant diseases particularly on wheat powdery mildew and cucumber gray mold, without ill effects on crops. A carbamate derivative represented by the general formula [I] {wherein X is a halogen atom, a C1-C6 alkyl group or the like, n is 0 or an integer of from 1 to 4, R1 is a C1-C6 alkyl group, R2 is a hydrogen atom, a C1-C6 alkyl group or the like, R3 is a hydrogen atom or a C1-C6 alkyl group, G is an oxygen atom, a sulfur atom or the like, Y is a hydrogen atom, a C1-C10 alkyl group, C2-C10 alkenyl group or the like, and Q is a hydrogen atom, a C1-C6 haloalkyl group, a phenyl group or the like} and an agricultural/horticultural fungicide containing the same as the active ingredient.Type: GrantFiled: February 5, 2002Date of Patent: November 2, 2004Assignees: Kumiai Chemical Industry Co., Ltd., Ihara Chemical Industry Co., Ltd.Inventors: Masami Ozaki, Shunichiro Fukumoto, Ryuji Tamai, Kazuhiro Ikegaya, Norihisa Yonekura, Takahiro Kawashima, Junetsu Sakai, Norimichi Muramatsu, Makikazu Takagaki, Kouzou Nagayama
-
Patent number: 6809097Abstract: Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1 represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3 and Y4 each independently represents carbon or nitrogen; R1 represents fluoro or hydrogen; m is an integer from 1 to 3; R3 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5 (wherein R4 and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1 represents —CH2— or a heteroatom linker group and R6 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may havType: GrantFiled: March 9, 1999Date of Patent: October 26, 2004Assignees: Zeneca Limited, Zeneca Pharma S.A.Inventors: Andrew Peter Thomas, Laurent Francois Andre Hennequin, Patrick Ple
-
Patent number: 6809098Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.Type: GrantFiled: August 21, 2002Date of Patent: October 26, 2004Assignee: AstraZeneca ABInventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
-
Patent number: 6806265Abstract: Compounds represented by formula I: wherein R2 is selected from the group consisting of H, (C1-4)alkyl, halo, haloalkyl, OH, (C1-6)alkoxy, NH(C1-4alkyl) or N(C1-4alkyl)2; R4 is H or Me; R5 is H or Me; R11 is H, (C1-4)alkyl, (C3-4)cycloalkyl and (C1-4)alkyl-(C3-4)cycloalkyl; A is a connecting chain of (C1-3)alkyl; B is O or S; n is 0 or 1; wherein when n is 0: Ring C is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted; and E is CONR12R13; CONHNR14R15; NR16COR17; NR18SO2(C1-6)alkyl; SO2NR19R20; or SO2R21; or when n is 1: Ring C is as defined above and E is a single bond or a connecting group; and Ring D is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted with from 1 to 5 substituents; or a salt orType: GrantFiled: May 6, 2003Date of Patent: October 19, 2004Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Serge Landry, Eric Malenfant, Julie Naud, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Patent number: 6794393Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: April 18, 2002Date of Patent: September 21, 2004Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
-
Patent number: 6790858Abstract: The present invention relates to a compound of formula (I): where R1-R6, W, X, and Y are defined herein, a composition includung the compound of formula (I), and a method for, e.g., male birth control, including administering an effective amount of a compound of formula (I) to a patient in need thereof.Type: GrantFiled: February 21, 2002Date of Patent: September 14, 2004Assignee: Zentaris AGInventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
-
Patent number: 6787541Abstract: Compounds of formula (I): wherein X is S. Compounds can be used for treating a disorder in which the blocking of purine receptors is beneficial.Type: GrantFiled: March 13, 2002Date of Patent: September 7, 2004Assignee: Vernalis Research LimitedInventors: Roger John Gillespie, Joanne Lerpiniere, Paul Richard Giles, Claire Elizabeth Dawson, David Bebbington
-
Patent number: 6787547Abstract: A compound, 7-chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administration of a pain-ameliorating effective amount of the compound and pharmaceutical compositions containing the compound.Type: GrantFiled: January 21, 2003Date of Patent: September 7, 2004Assignee: Astrazeneca ABInventors: Thomas Michael Bare, Dean Gordon Brown, Megan Murphy, Rebecca Ann Urbanek, Wenhua Xiao
-
Patent number: 6787653Abstract: A process for preparing a biphenylcarboxylic acid amide derivative represented by the following formula (1): wherein, R1, R2 and R3 each independently represents a hydrogen atom or a substituent, which comprises reacting, in the presence of a metal catalyst, a halogenobenzoic acid derivative represented by the following formula (2): wherein, X represents a halogen atom with a compound represented by the following formula (3): wherein, R1, R2 and R3 have the same meanings as described above, and Y represents an leaving group having an element selected from the group consisting of boron, silicon, zinc, tin and magnesium; or salt thereof. According to the present invention, biphenylcarboxylic acid amide derivatives of the formula (1) or salts thereof having excellent inhibitory activity against IgE antibody production can be prepared by the reduced number of steps, conveniently, at lower cost and in a high yield.Type: GrantFiled: June 6, 2002Date of Patent: September 7, 2004Assignee: Kowa Co., Ltd.Inventors: Hiroyuki Ishiwata, Seiichi Sato, Mototsugu Kabeya, Soichi Oda
-
Patent number: 6784173Abstract: Compounds of formula I wherein A, R1 and R2 are defined in the specification. These compounds are useful as HDAC inhibitors. Also disclosed are methods of making and using said compounds.Type: GrantFiled: June 11, 2002Date of Patent: August 31, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Ulrike Leser-Reiff, Tim Sattelkau, Gerd Zimmermann
-
Patent number: 6784200Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.Type: GrantFiled: May 1, 2003Date of Patent: August 31, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
-
Patent number: 6784182Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.Type: GrantFiled: February 4, 2002Date of Patent: August 31, 2004Assignee: Eli Lilly and CompanyInventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
-
Patent number: 6784180Abstract: The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.Type: GrantFiled: September 9, 2002Date of Patent: August 31, 2004Assignee: Eli Lilly and CompanyInventors: John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
-
Patent number: 6780864Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents ═C or —N; —R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl—methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.Type: GrantFiled: August 14, 2001Date of Patent: August 24, 2004Assignee: DUPHAR International Research BVInventors: Roelof Feenstra, Johannes A. M. Van Der Heijden, Cornelis G. Kruse, Stephen K. Long, Johannes Mos, Gerben M. Visser, Gustaaf J. M. Van Scharrenburg, Gerrit P. Toorop
-
Patent number: 6774129Abstract: The present invention concerns the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein each R1 is independently hydrogen, halogen, C1-6alkyl, nitro, hydroxy or C1-4alkyloxy; Alk is C1-6alkanediyl; n is 1 or 2; p is 0, 1 or 2; D is an optionally substituted mono-, bi- or tricyclic nitrogen containing heterocycle having central &agr;2-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine.Type: GrantFiled: April 16, 2002Date of Patent: August 10, 2004Assignee: Janssen Pharmaceutica N.V.Inventors: Ludo Edmond Josephine Kennis, Serge Maria Aloysius Pieters, François Paul Bischoff